Anti-PD-L1 antibody treatment can improve the response of pancreatic ductal adenocarcinoma to radiotherapy and enhance the effect of radiotherapy in preventing the formation of liver metastases27. This evidence concerns the gene CD274 and pancreatic ductal adenocarcinoma.